Transaction DateRecipientSharesTypePriceValue
12th June 2019Allan L Goldstein228,000Bona fide gift$0.00
6th January 2019Allan L Goldstein208,912Conversion of derivative$0.06$12,534.72
6th January 2019Joseph C Mcnay522,280Conversion of derivative$0.06$31,336.80
Regene Rx Biopharmaceuticals
Regene Rx Biopharmaceuticals logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 9/10.


RegeneRx Biopharmaceuticals, Inc. focuses on the development of a novel therapeutic peptide, Thymosin beta 4, or Tß4. The company was founded by Allan L. Goldstein on May 13, 1982 and is headquartered in Rockville, MD.


Ticker: RGRX
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 707511
Employees: 4
Exchange: US OTC
Auditor Opinion:

Disclosure Language changes
Red Flags
Fundamentals